Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 2,509 shares at $454.84 ($1.1M) on 2025-08-18, disclosed to the SEC on 2025-08-19.
Open-market sale of $1.1M ALNY by CSO & EVP, Head of Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $447.98 | 39 | $17K | 1.5% |
| 2 | $449.92 | 90 | $40K | 3.6% |
| 3 | $450.92 | 39 | $18K | 1.5% |
| 4 | $451.99 | 103 | $47K | 4.1% |
| 5 | $452.96 | 329 | $149K | 13.1% |
| 6 | $452.96 | 329 |
| $149K |
| 13.1% |
| 7 | $454.04 | 543 | $247K | 21.7% |
| 8 | $454.04 | 543 | $247K | 21.7% |
| 9 | $454.84 | 241 | $110K | 9.6% |
| 10 | $454.84 | 241 | $110K | 9.6% |
| 11 | $455.82 | 12 | $5K | 0.5% |
| Total | $453.54 avg | 2,509 | $1.1M | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $1.3M | — | Filing → |
| ALNY | SELL | 2026-01-14 | $1.4M | — | Filing → |
| ALNY | SELL | 2025-11-19 | $7.1M | — | Filing → |